BRAF

News

Pfizer builds on Braftovi bowel cancer OK with survival data

Pfizer's Braftovi - just approved by the FDA as a first-line treatment for colorectal cancer based on response data - also extends patient survival.

News

Novartis bags FDA okay for BRAF-positive tumour combination

Novartis' two-drug regimen of Tafinlar and Mekinist has been approved by the FDA as the first therapy for solid tumours that have a BRAF V600E mutation – regardless of where they occur in t

News

EMA advisors say CSL's Tavneos should be pulled from sale

Pressure is building on Amgen to withdraw rare disease therapy Tavneos, after the CHMP recommended its marketing authorisation by revoked in the EU.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Digital

Discover a new era of healthcare panel engagement: Grounded ...

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.

Editor's Picks